To verify this function, we constructed an olaparib‐resistant PDX mouse model with KLF5 high expression and found that olaparib combined with SAHA significantly inhibited subcutaneous tumor formation compared to SAHA or olaparib treatment (Figure 8J,K). This evidence concerns the gene KLF5 and neoplasm.